ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc.

CLPT·NASDAQ

$13.30

+7.5%
HealthcareMedical - Devices

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

At a Glance

Live Snapshot
Market Cap$398.86M
EPS-0.9000
P/E Ratio-14.78
Earnings Date08/11/2026
3Y+80.0%
5Y+188.0%
10Y+543.0%
3Y+55.0%
5Y+277.0%
10Y+216.0%
3Y+48.0%
5Y+206.0%
10Y+311.0%
ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. Profit Bridge

CLPT · NASDAQ
Revenue36.97M
Cost of Goods Sold (14.28M)
Gross Profit22.69M
Operating Expenses (46.86M)
Operating Income-24.16M
Interest Expense (2.39M)
Other Income/Expense-1.32M
Pretax Income-25.48M
Income Tax (55.00K)
Net Income-25.54M
Net Income
-25.54M

Profitability Analysis

Gross Margin

61.4%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

-65.4%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-69.1%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

ClearPoint Neuro, Inc. Income Statement

CLPT • NASDAQ

ClearPoint Neuro, Inc. Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010
REVENUE
37M
31.4M
24M
20.6M
16.3M
12.8M
11.2M
7.4M
7.4M
5.7M
4.6M
3.6M
3.9M
5.1M
3.8M
2.7M
GROSS PROFIT
(14.3M)
(12.3M)
(10.3M)
(7M)
(5.2M)
(3.7M)
(3.9M)
(2.4M)
(2.9M)
(2.6M)
(2M)
(1.9M)
(1.4M)
(555.7K)
(656.4K)
(16.3K)
22.7M
19.1M
13.6M
13.5M
11.1M
9.1M
7.3M
4.9M
4.5M
3.1M
2.6M
1.7M
2.5M
4.5M
3.2M
2.7M
OPERATING INCOME
(46.9M)
(38.9M)
(36.1M)
(29.9M)
(24.5M)
(15.3M)
(11.9M)
(10.2M)
(10.8M)
(10.6M)
(10.3M)
(11.3M)
(10M)
(7.6M)
(9.1M)
(10.4M)
(33M)
(26.5M)
(24.4M)
(19M)
(15.2M)
(10.7M)
(9.1M)
(7.9M)
(8M)
(8M)
(8.4M)
(8M)
(7.1M)
(6M)
(4.8M)
(4.7M)
(13.9M)
(12.4M)
(11.7M)
(10.9M)
(9.3M)
(4.7M)
(2.8M)
(2.3M)
(2.8M)
(2.6M)
(2M)
(3.3M)
(2.9M)
(1.6M)
(4.3M)
(5.7M)
-24.2M
-19.7M
-22.4M
-16.3M
-13.4M
-6.2M
-4.6M
-5.2M
-6.3M
-7.5M
-9M
-5.3M
-7.5M
-3.1M
-5.9M
-9.5M
PRE-TAX INCOME
(2.4M)
(0.0)
(0.0)
(81K)
(973K)
(1.4M)
(955K)
(980.4K)
(872.9K)
(1.1M)
(1.3M)
(1M)
(499.8K)
(2.6M)
(2.5M)
(1.6M)
-1.2M
872K
386K
-81K
-973K
-1.4M
-955K
-980.4K
-872.9K
-1.1M
-1.2M
-1M
-475.3K
-2.6M
-2.5M
-1.6M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(364.0)
(16.7K)
(0.0)
(0.0)
(0.0)
(0.0)
(2.8K)
(0.0)
(0.0)
-1.3M
832K
357K
-103K
-1M
-562K
-946K
-915.7K
-831.5K
-581.2K
524.9K
795.9K
388.5K
-2.6M
-2.4M
61.1K
-25.5M
-18.9M
-22.1M
-16.4M
-14.4M
-6.8M
-5.5M
-6.2M
-7.2M
-8.1M
-8.4M
-4.5M
-7.1M
-5.7M
-8.3M
-9.5M
NET INCOME
(55K)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(2.2M)
(0.0)
(0.0)
-25.5M
-18.9M
-22.1M
-16.4M
-14.4M
-6.8M
-5.5M
-6.2M
-7.2M
-8.1M
-8.4M
-4.5M
-7.1M
-5.7M
-8.3M
-9.5M

SEC Filings

CLPT - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 21, 2026
May 20, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 13, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 13, 2026
May 13, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 10, 2026
April 10, 2026
2026
8-K

8-K 2026

N/A

March 17, 2026
March 17, 2026
2026
10-K

10-K 2025 FY

FY

March 17, 2026
December 31, 2025
2025
8-K/A

8-K/A 2025 (Amended)

N/A

February 05, 2026
November 20, 2025
2025
S-3

S-3

N/A

January 14, 2026
January 14, 2026
 
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
8-K

8-K 2026

N/A

January 05, 2026
January 05, 2026
2026
Showing 1 to 10 of 314 filings